Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

被引：0

作者：

Pagani, Olivia

Regan, Meredith M.

Walley, Barbara

Fleming, Gini F.

Colleoni, Marco

Lang, Istvan

Gomez, Henry Leonidas

Tondini, Carlo

Burstein, Harold J.

Perez, Edith A.

Ciruelos, Eva

Stearns, Vered

Bonnefoi, Herve R.

Martino, Silvana

Geyer, Charles E.

Rabaglio-Poretti, Manuela

Coates, Alan S.

Gelber, Richard D.

Goldhirsch, Aron

Francis, Prudence A.

机构：

[1] SAKK, Inst Oncol Southern Switzerland, Lugano Viganello, Switzerland

[2] IBCSG, Lugano Viganello, Switzerland

[3] Dana Farber Canc Inst, IBCSG Stat Ctr, Boston, MA 02115 USA

[4] NCIC Clin Trials Grp, Kingston, ON, Canada

[5] Univ Chicago, Med Ctr & Alliance, Chicago, IL 60637 USA

[6] European Inst Oncol, Milan, Italy

[7] IBCSG, Milan, Italy

[8] Natl Inst Oncol, Budapest, Hungary

[9] Inst Natl Enfermedades Neoplas, Lima, Peru

[10] IBCSG, Lima, Peru

[11] Osp Papa Giovanni XXIII, Bergamo, Italy

[12] Dana Farber Canc Inst & Alliance, Boston, MA USA

[13] Mayo Clin & Alliance, Jacksonville, FL USA

[14] Univ Hosp 12 Octubre, Madrid, Spain

[15] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[16] ECOG, Baltimore, MD USA

[17] Bergonie Inst, Bordeaux, France

[18] EORTC, Bordeaux, France

[19] Angeles Clin & Res Inst, Santa Monica, CA USA

[20] SWOG, Santa Monica, CA USA

[21] Virginia Commonwealth Univ, Massey Canc Ctr, Sch Med, Richmond, VA USA

[22] NRG Oncol, Richmond, VA USA

[23] Inst Med Oncol, Bern, Switzerland

[24] Int Breast Canc Study Grp, Bern, Switzerland

[25] ANZBCTG, Peter MacCallurn Canc Ctr, Melbourne, Vic, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA1

引用

页数：1

共 50 条

[41] Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials (vol 23, pg 382, 2022)
Bradley, R.
LANCET ONCOLOGY, 2022, 23 (04): : E161 - E161
[42] Ribociclib (RIB) plus non-steroidal aromatase inhibitor (NSAI) plus goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study
Im, S-A.
Sohn, J.
Tripathy, D.
Chow, L.
Lee, K. S.
Jung, K. H.
Babu, G.
Im, Y-H.
El Saghir, N.
Liu, M-C.
Diaz-Padilla, I.
Alam, J.
Kong, O.
Miller, M.
Lu, Y-S.
ANNALS OF ONCOLOGY, 2018, 29
[43] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)
Harbeck, N.
Villanueva, R.
Franke, F.
Babu, G.
Wheatley-Price, P.
Im, Y-H.
Altundag, K.
Lanoue, B.
Alam, J.
Chandiwana, D.
Colleoni, M.
ANNALS OF ONCOLOGY, 2018, 29
[44] PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy
Kornblum, N. S.
Manola, J.
Klein, P.
Ramaswamy, B.
Brufsky, A.
Stella, P. J.
Burnette, B.
Telli, M.
Makower, D. F.
Leach, J.
Truica, C. I.
Wolff, A. C.
Soori, G. S.
Haley, B.
Nagarajan, A.
Wassenaar, T. R.
Goldstein, L.
Miller, K. D.
Sparano, J. A.
CANCER RESEARCH, 2017, 77
[45] Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) locally advanced or metastatic breast cancer: Fourth interim analysis from the RIBANNA study
Luftner, Diana
Brucker, Cosima
Decker, Thomas
Fasching, Peter
Gohler, Thomas
Jackisch, Christian
Janssen, Jan
Kohler, Andreas
Ludtke-Heckenkamp, Kerstin
van Mackelenbergh, Marion
Marme, Frederik
Nusch, Arnd
Rautenberg, Beate
Reimer, Toralf
Schmidt, Marcus
Weide, Rudolf
Wimberger, Pauline
Nabieva, Naiba
Roos, Christian
Wockel, Achim
CANCER RESEARCH, 2022, 82 (04)
[46] Gruppo Italiano Mammella (GIM) 10-CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR plus ) early breast cancer (EBC)
Lambertini, M.
Guarneri, V.
Caremoli, E. R.
Rocca, A.
Montemurro, F.
De laurentiis, M.
Giordano, M.
De Placido, S.
Bisagni, G.
Garrone, O.
Ferzi, A.
Giovanardi, F.
Cognetti, F.
Amaducci, L.
Bernardo, A.
Livi, L.
Bighin, C.
Poggio, F.
Ballestrero, A.
Del Mastro, L.
ANNALS OF ONCOLOGY, 2020, 31 : S47 - S47
[47] Poster Discussion Session Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/ human epidermal growth factor receptor-negative (HR+/HER2-) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).
Rugo, Hope S.
O'Shaughnessy, Joyce
Jhaveri, Komal L.
Tolaney, Sara M.
Cardoso, Fatima
Bardia, Aditya
Maheshwari, Vikalp Kumar
Tripathi, Sandeep
Pathak, Purnima
Haftchenary, Sina
Fasching, Peter A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).
De Laurentiis, Michelino
Costa, Luis
Gligorov, Joseph
Knop, Ann
Senkus-Konefka, Elzbieta
Garcia-Saenz, Jose A.
Schmid, Peter
Heniquez, Aurelia
Serra, Paolo
Reising, Albert
Kuemmel, Sherko
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor plus breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)
Mamounas, Eleftherios P.
Bandos, Hanna
Lembersky, Barry C.
Jeong, Jeon Hyeon
Geyer, Charles E., Jr.
Rastogi, Priya
Fehrenbacher, Louis
Graham, Mark L.
Chia, Stephen K.
Brufsky, Adam M.
Walshe, Janice M.
Soori, Gamini S.
Dakhil, Shaker R.
Seay, Thomas E.
Wade, James L., III
McCarron, Edward C.
Paik, Soonmyung
Swain, Sandra M.
Wickerham, D. Lawerence
Wolmark, Norman
CANCER RESEARCH, 2020, 80 (04)
[50] Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.
Lueftner, Diana
Brucker, Cosima
Decker, Thomas
Fasching, Peter A.
Goehler, Thomas
Jackisch, Christian
Janssen, Jan
Koehler, Andreas
Luedtke-Heckenkamp, Kerstin
Van Mackelenbergh, Marion
Marme, Frederik
Nusch, Arnd
Rautenberg, Beate
Reimer, Toralf
Schmidt, Marcus
Weide, Rudolf
Wimberger, Pauline
Nabieva, Naiba
Roos, Christian
Woeckel, Achim
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →